The U.K.-based drugmaker posted disappointing profits for the first quarter as sales took a backwards step, partly because of revenue lost in the sale of over-the-counter products.
BIO and the International Federation of Pharmaceutical Manufacturers & Associations warn that more funding is needed to maintain current immunization rates while adding new vaccines to programs.
While the success rate in developing new disease treatments remains alarmingly low, a cadre of R&D executives from some of the world's biggest drug developers insisted at BIO that they've zeroed in on a number of ways to boost the chance a promising drug will actually reach patients.
Maverick states could cost Big Pharma big money. Though many drugmakers have wrapped up marketing settlements with the federal government--and states willing to go along--they're now facing claims from state attorneys general who are bold, stubborn, ambitious, or all of the above.
The London-based drug giant has partnered with veteran life sciences investors at Avalon Ventures to bankroll a crop of drug-hunting startups in San Diego, with GSK committing the bulk of the alliance's $495 million to fuel the new companies.
Sanofi Pasteur is ready to aim its new 6-in-1 infant vaccine at rival GlaxoSmithKline. The vaccine maker won European approval for the immunization, putting Glaxo's Infanrix Hexa on notice for the first time since 2005.
Two big-time drugmakers are having to put their plans on hold thanks to problems with contract manufacturers, with GlaxoSmithKline facing a prolonged drug shortage and Allergan enduring an FDA rejection.
GlaxoSmithKline CEO Andrew Witty has high hopes for an experimental pill his company is developing for anemia, as the drug could offer an oral alternative to injected EPO therapies.
The agency advisers weren't unanimous in backing GSK's follow-up to now-off-patent Advair, however.
China and India may top the list of fastest-growing pharma markets, but Brazil is no slouch, either. Drugmakers are wheeling and dealing there at an increasingly faster pace, as companies like Merck and Reckitt Benckiser join old-timers like Sanofi and GlaxoSmithKline in beefing up there.